Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Revenues
License revenue	$ 4,303	$ 5,025	$ 4,355
License revenue from related party		2,000	220
Reagent sales	213	257	326
Grant revenue	73	306	1,219
Total revenues	4,589	7,588	6,120
Costs of revenues
Licensing costs (including amounts to related parties)	861	1,405	885
Costs of reagent sales (including amounts to related parties)	98	98	122
Research and development (including amounts to related parties)	45,482	17,279	4,961
General and administrative (including amounts to related parties)	23,590	11,912	3,851
Other operating expenses (income)	(102)	31	(17)
Total operating expenses	69,929	30,725	9,802
Loss from operations	(65,340)	(23,137)	(3,682)
Other Income (Expense)
Investment income	1,938	346
Interest expense		(20)	(321)
Total other income (expense)	1,938	326	(321)
Loss before income taxes	(63,402)	(22,811)	(4,003)
Income Tax Benefit	435	0	0
Net loss	(62,967)	(22,811)	(4,003)
Other Comprehensive Income (Loss)
Unrealized gain (loss) on available-for-sale securities, net of income tax expense of $435 for the year ended December 31, 2016	686	(719)
Total other comprehensive income (loss)	686	(719)
Comprehensive loss	(62,281)	(23,530)	(4,003)
Reconciliation of net loss to net loss applicable to common stockholders
Net loss	(62,967)	(22,811)	(4,003)
Net accretion and dividends on convertible preferred stock		(1,747)	(815)
Net gain on extinguishment of convertible preferred stock		759
Net loss applicable to common stockholders	$ (62,967)	$ (23,799)	$ (4,818)
Basic and diluted net loss per common share	$ (2.38)	$ (2.59)	$ (1.82)
Weighted-average basic and diluted common shares	26,409	9,173	2,643